Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm study to evaluate the safety and efficacy of bortezomib
plus dexamethasone for acquired pure red cell aplasia failure or relapse after first-line
treatment.